Drug Profile
Elraglusib - Actuate Therapeutics
Alternative Names: 9 ING 41Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Northwestern University; University of Illinois at Chicago
- Developer Actuate Therapeutics; Incyte Corporation; Levine Cancer Institute; University of Kansas Medical Center
- Class Antineoplastics; Benzofurans; Dioxolanes; Indoles; Pyrroles; Small molecules
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenoid cystic carcinoma; Myelofibrosis; Neuroblastoma; Pancreatic cancer; Salivary gland cancer
- Phase I/II Cancer
- Preclinical Brain cancer; Chronic lymphocytic leukaemia; Colorectal cancer
Most Recent Events
- 18 Jan 2024 Actuate Therapeutics completes a phase II clinical trials in Myelofibrosis (Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT04218071)
- 01 Aug 2023 Elraglusib - Actuate Therapeutics receives Orphan Drug status for Pancreatic cancer (Combination therapy, Late-stage disease) in USA
- 20 Jun 2023 Phase-I/II clinical trials in Cancer (Second-line therapy or greater, Refractory metastatic disease, Combination therapy) in France (IV) (NCT03678883)